V
35.53
-0.48 (-1.33%)
| Previous Close | 36.01 |
| Open | 35.79 |
| Volume | 1,510,106 |
| Avg. Volume (3M) | 2,977,288 |
| Market Cap | 4,105,644,032 |
| Price / Book | 6.42 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Diluted EPS (TTM) | -1.54 |
| Total Debt/Equity (MRQ) | 0.11% |
| Current Ratio (MRQ) | 25.86 |
| Operating Cash Flow (TTM) | -152.54 M |
| Levered Free Cash Flow (TTM) | -102.10 M |
| Return on Assets (TTM) | -14.99% |
| Return on Equity (TTM) | -19.99% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Viking Therapeutics, Inc. | Bearish | Mixed |
AIStockmoo Score
-0.3
| Analyst Consensus | -2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.30 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 70.06% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AUBUCHON NEIL WILLIAM | 34.66 | - | 4,475 | 155,104 |
| Aggregate Net Quantity | 4,475 | |||
| Aggregate Net Value ($) | 155,104 | |||
| Aggregate Avg. Buy ($) | 34.66 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AUBUCHON NEIL WILLIAM | Officer | 10 Mar 2026 | Buy (+) | 4,475 | 34.66 | 155,104 |
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 |
| 12 Jan 2026 | Announcement | Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity |
| 10 Jan 2026 | CNBC | 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market |
| 08 Jan 2026 | Announcement | Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity |
| 07 Jan 2026 | Announcement | Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer |
| 05 Jan 2026 | Announcement | Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |